IP Library › Granted Patent US 12,427,147
Granted Patent B2
US 12,427,147 · App. 17/289,201 · Granted Sep 30, 2025

Retinal ganglion cell death inhibitor

Inventors: Yayoi Kishimoto (Osaka, JP); Chiho Yabuta (Osaka, JP)
Assignee: SENJU PHARMACEUTICAL CO., LTD.
A61K31/519A61K31/4418A61K31/496A61P27/02C07K16/22C07K16/2863C07K2317/54C07K2317/55C07K2317/56C07K2317/622C07K2317/626
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,427,147
App. No.
17/289,201
Granted
Sep 30, 2025
Kind
B2
Abstract

The present invention relates to a retinal ganglion cell death suppressor comprising a BMPR signal transduction inhibitor, a drug comprising a BMPR signal transduction inhibitor for protecting retinal neurons, and a pharmaceutical composition using these for preventing or treating a disease involving retinal ganglion cell death, such as glaucoma, diabetic retinopathy and retinal vascular occlusion.

Claims (18)

1. A method for suppressing retinal ganglion cell death comprising culturing retinal ganglion cells in the presence of an effective amount of an Activin Receptor-like Kinase 3 (ALK3) signal transduction inhibitor, wherein the ALK3 signal transduction inhibitor is at least one selected from the group consisting of an anti-ALK3 antibody or a fragment thereof that binds ALK3, an anti-BMP4 antibody or a fragment thereof that binds BMP4, LDN-193189 (4-[6-(4-piperazin-1-yl-phenyl)-pyrazolo[1,5-α]pyrimidin-3-yl]-quinoline), 2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine, K02288 (3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]-phenol), DMH-1 (4-[6-[4-(1-methylethoxy)phenyl]pyrazolo[1,5-α]pyrimidin-3-yl]-quinoline), LDN-212854 (5-(6-(4-(1-piperazinyl)phenyl)pyrazolo[1,5-α]pyrimidin-3-yl)quinoline), LDN-214117 (1-[4-[6-methyl-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]phenyl] piperazine), ML347 (5-[6-(4-methoxyphenyl)pyrazolo[1,5-α]pyrimidin-3-yl]quinoline), an ALK3 antisense nucleic acid or siRNA, and a BMP4 antisense nucleic acid or siRNA, wherein the fragment is at least one selected from the group consisting of a Fab, a F(ab′)2, a Fv, a scFv, a scFv-Fc, a minibody, and a diabody.

2. The method according to claim 1 , wherein the retinal ganglion cells are cells for transplantation.

3. A method for protecting a retinal neuron comprising culturing the retinal neuron in the presence of an effective amount of an Activin Receptor-like Kinase 3 (ALK3) signal transduction inhibitor, wherein the ALK3 signal transduction inhibitor is at least one selected from the group consisting of an anti-ALK3 antibody or a fragment thereof that binds ALK3, an anti-BMP4 antibody or a fragment thereof that binds BMP4, LDN-193189 (4-[6-(4-piperazin-1-yl-phenyl)-pyrazolo[1,5-α]pyrimidin-3-yl]-quinoline), 2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine, K02288 (3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]-phenol), DMH-1 (4-[6-[4-(1-methylethoxy)phenyl]pyrazolo[1,5-α]pyrimidin-3-yl]-quinoline), LDN-212854 (5-(6-(4-(1-piperazinyl)phenyl)pyrazolo[1,5-α]pyrimidin-3-yl)quinoline), LDN-214117 (1-[4-[6-methyl-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]phenyl] piperazine), ML347 (5-[6-(4-methoxyphenyl)pyrazolo[1,5-α]pyrimidin-3-yl]quinoline), an ALK3 antisense nucleic acid or siRNA, and a BMP4 antisense nucleic acid or siRNA, wherein the fragment is at least one selected from the group consisting of a Fab, a F(ab′)2, a Fv, a scFv, a scFv-Fc, a minibody, and a diabody.

4. A method for treating a disease involving retinal ganglion cell death comprising administering an effective amount of an Activin Receptor-like Kinase 3 (ALK3) signal transduction inhibitor to a subject in need of the treatment,

wherein the ALK3 signal transduction inhibitor is at least one selected from the group consisting of an anti-ALK3 antibody or a fragment thereof that binds ALK3, an anti-BMP4 antibody or a fragment thereof that binds BMP4, LDN-193189 (4-[6-(4-piperazin-1-yl-phenyl)-pyrazolo[1,5-α]pyrimidin-3-yl]-quinoline), 2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine, K02288 (3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]-phenol), DMH-1 (4-[6-[4-(1-methylethoxy)phenyl]pyrazolo[1,5-α]pyrimidin-3-yl]-quinoline), LDN-212854 (5-(6-(4-(1-piperazinyl)phenyl)pyrazolo[1,5-α]pyrimidin-3-yl)quinoline), LDN-214117 (1-[4-[6-methyl-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]phenyl] piperazine), ML347 (5-[6-(4-methoxyphenyl) pyrazolo[1,5-α]pyrimidin-3-yl]quinoline), an ALK3 antisense nucleic acid or siRNA, and a BMP4 antisense nucleic acid or siRNA,

wherein the disease involving retinal ganglion cell death is selected from the group consisting of glaucoma, retinal vascular occlusion, ischemic optic neuropathy, and Leber disease, and

wherein the fragment is at least one selected from the group consisting of a Fab, a F(ab′)2, a Fv, a scFv, a scFv-Fc, a minibody, and a diabody.

5. The method according to claim 4 , wherein the ALK3 signal transduction inhibitor is at least an anti-ALK3 antibody or a fragment thereof that binds ALK3.

6. The method according to claim 4 , wherein the ALK3 signal transduction inhibitor is at least an anti-BMP4 antibody or a fragment thereof that binds BMP4.

7. The method according to claim 4 , wherein the ALK3 signal transduction inhibitor is at least one selected from the group consisting of LDN-193189 (4-6-(4-piperazin-1-yl-phenyl)-pyrazolo[1,5-α]pyrimidin-3-yl]-quinoline), 2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine, K02288 (3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]-phenol), DMH-1 (4-[6-[4-(1-methylethoxy)phenyl]pyrazolo[1,5-α]pyrimidin-3-yl]-quinoline), LDN-212854 (5-(6-(4-(1-piperazinyl)phenyl)pyrazolo[1,5-α]pyrimidin-3-yl)quinoline), LDN-214117 (1-[4-[6-methyl-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]phenyl] piperazine), and ML347 (5-[6-(4-methoxyphenyl)pyrazolo[1,5-α]pyrimidin-3-yl]quinoline).

8. The method according to claim 4 , wherein the ALK3 signal transduction inhibitor is at least an ALK3 antisense nucleic acid or siRNA.

9. The method according to claim 4 , wherein the ALK3 signal transduction inhibitor is at least a BMP4 antisense nucleic acid or siRNA.

10. The method according to claim 4 , wherein the disease involving retinal ganglion cell death is glaucoma.

11. The method according to claim 10 , wherein the ALK3 signal transduction inhibitor is at least an anti-ALK3 antibody or a fragment thereof that binds ALK3.

12. The method according to claim 10 , wherein the ALK3 signal transduction inhibitor is at least an anti-BMP4 antibody or a fragment thereof that binds BMP4.

13. The method according to claim 10 , wherein the ALK3 signal transduction inhibitor is at least one selected from the group consisting of LDN-193189 (4-[6-(4-piperazin-1-yl-phenyl)-pyrazolo[1,5-α]pyrimidin-3-yl]-quinoline), 2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine, K02288 (3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]-phenol), DMH-1 (4-[6-[4-(1-methylethoxy)phenyl]pyrazolo[1,5-α]pyrimidin-3-yl]-quinoline), LDN-212854 (5-(6-(4-(1-piperazinyl)phenyl)pyrazolo[1,5-α]pyrimidin-3-yl) quinoline), LDN-214117 (1-[4-[6-methyl-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]phenyl] piperazine), and ML347 (5-[6-(4-methoxyphenyl)pyrazolo[1,5-α]pyrimidin-3-yl]quinoline).

14. The method according to claim 10 , wherein the ALK3 signal transduction inhibitor is at least an ALK3 antisense nucleic acid or siRNA.

15. The method according to claim 10 , wherein the ALK3 signal transduction inhibitor is at least a BMP4 antisense nucleic acid or siRNA.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2021
From: KISHIMOTO, YAYOI; YABUTA, CHIHO
To: SENJU PHARMACEUTICAL CO., LTD.
Reel/Frame 056263/0836 →
Priority Claims (1)
JP 2018-204891 · Oct 31, 2018 · national
Continuity (1)
Related Publication 20210346386A1 · Nov 11, 2021
References Cited (49)
US 20050118585A1 · Clark et al. · 2005 [cited by applicant]
US 20100093760A1 · Yu · 2010 [cited by examiner]
US 20100292454A1 · Mishina · 2010 [cited by examiner]
US 20130089560A1 · Chartier-Courtaud · 2013 [cited by examiner]
US 20150030572A1 · Zack et al. · 2015 [cited by applicant]
US 20150050360A1 · Tan · 2015 [cited by examiner]
US 20150376625A1 · Oestergaard · 2015 [cited by examiner]
US 20180162932A1 · Krishnadath et al. · 2018 [cited by applicant]
US 20180355319A1 · Yamamoto et al. · 2018 [cited by applicant]
JP 2005518788A · 2005 [cited by applicant]
JP 2017537603A · 2017 [cited by applicant]
WO WO2007123402A2 · 2007 [cited by examiner]
WO WO2008030611A2 · 2008 [cited by examiner]
WO WO2010114860A1 · 2010 [cited by examiner]
WO WO2015054526A2 · 2015 [cited by applicant]
WO WO2015054526A3 · 2015 [cited by applicant]
WO WO2016032263A1 · 2016 [cited by applicant]
WO WO2017026462A1 · 2017 [cited by applicant]
Agarwal et al. An update on inflammatory choroidal neovascularization: epidemiology, multimodal imaging, and management. J Ophthal Inflamm Infect 8: 13, 2018 (18 total pages). [cited by examiner]
Belforte et al. Metabolic stress in glaucoma engages early activation of the energy biosensor AMPK leading to neuronal dysfunction. Investigat Ophthalmol Vis Sci 58: 2958, 2017. [cited by examiner]
Calpe et al. Effective Inhibition of Bone Morphogenetic Protein Function by Highly Specific Llama-Derived Antibodies. Mol Cancer Ther 14(11): 2527-2540, 2015. [cited by examiner]
Conley et al. Nanoparticles for retinal gene therapy. Prog Retinal Eye Res 29: 376-397, 2010. [cited by examiner]
Hoorbakht et al. Optic Neuritis, its Differential Diagnosis and Management. Open Ophthalmol J 6: 65-72, 2012. [cited by examiner]
Bhattacharya et al. Impact of genetic variation on three dimensional structure and function of proteins. PLoS One 12(3): e0171355, 2017. [cited by examiner]
Bork, P. Powers and pitfalls in sequence analysis: the 70% hurdle. Genome Res 10: 398-400, 2000. [cited by examiner]
Bork, P. Go hunting in sequence databases but watch out for the traps. Trends in Genetics 12(10): 425-427, 1996. [cited by examiner]
Brenner. S.E. Errors in genome annotation. Trends in Genetics 15:132-133, 1999. [cited by examiner]
Deng et al. BMP4 promotes hepatocellular carcinoma proliferation by autophagy activation through JNK1-mediated Bcl-2 phosphorylation. J Exp Clin Cancer Res 37: 156, 2018 (plus supplemental information materials) (18 tot… [cited by examiner]
Doerks et al. Protein annotation: detective work for function prediction. Trends in Genetics 14:248-250, 1998. [cited by examiner]
Fenton et al. Rheostat positions: a new classification of protein positions relevant to pharmacogenomics. Medicinal Chem Res 29: 1133-1146, 2020. [cited by examiner]
Lagenfeld et al. Bone Morphogenetic Protein Type I Receptor Antagonists Decrease Growth and Induce Cell Death of Lung Cancer Cell Lines. PLoS One 8(4): e61256, 2013 (15 total pages). [cited by examiner]
Lieven et al. Retinal Ganglion Cell Axotomy Induces an Increase in Intracellular Superoxide Anion. Invest Ophthalmol Vis Sci 47: 1477-1485, 2006. [cited by examiner]
Liu et al. Bone Morphogenetic Protein 4 (BMP4): A Regulator of Capsule Chondrogenesis in the Developing Mouse Inner Ear. Dev Dynamics 226: 427-438, 2003. [cited by examiner]
Murakami et al. Regulatory expression of genes related to metastasis by TGF-B and activin A in B16 murine melanoma cell. Mol Biol Rep 37: 1279-1286, 2010. [cited by examiner]
Raffaele et al. Compared antioxidant activity among corticosteroids on cultured retinal pigment epithelial cells. Grafes Arch Clin Exp Ophathalmol 254: 2411-2416, 2016. [cited by examiner]
Roggia et al. Characterization of retinal pigment epithelial cells in rd1 mouse model of retinal degeneration. Invest Ophthalmol Vis Sci 56: 3642, 2015 (2 pages). [cited by examiner]
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotechnol 18(I):34-39 2000. [cited by examiner]
Smith et al. The challenges of genome sequence annotation or “the devil is in the details”. Nature Biotechnol 15: 1222-1223, 1997. [cited by examiner]
Sorescu et al. Bone Morphogenic Protein 4 Produced in Endothelial Cells by Oscillatory Shear Stress Induces Monocyte Adhesion by Stimulating Reactive Oxygen Species Production From a Nox1-Based NADPH Oxidase. Circ Res 9… [cited by examiner]
Tokuriki et al. Stability effects of mutations and protein evolvability. Curr Opin Structural Biol 19: 596-604, 2009. [cited by examiner]
White et al. Menadione-treated synaptosomes as a model for post-ischaemic neuronal damage. Biochem J 253: 425-433, 1988. [cited by examiner]
Yu et al. Bone Morphogenetic Protein (BMP) Type II Receptor Deletion Reveals BMP Ligand-specific Gain of Signaling in Pulmonary Artery Smooth Muscle Cells. J Biol Chem 280(26): 24443-24450, 2005. [cited by examiner]
Sluch et al., “Enhanced Stem Cell Differentiation and Immunopurification of Genome Engineered Human Retinal Ganglion Cells,” [cited by applicant]
European Patent Office, Extended European Search Report in European Patent Application No. 19879493.5 (Oct. 11, 2022). [cited by applicant]
Belforte et al., “Metabolic stress in glaucoma engages early activation of the energy biosensor AMPK leading to neuronal dysfunction,” [cited by applicant]
Hussein et al., “BMP2 and 4 Contribute to Retinal Endothelial Cell Barrier Dysfunction in Diabetic Retinopathy: Role of p38 MAPK Pathway,” [cited by applicant]
Ueki et al., “Activation of BMP-Smad1/5/8 Signaling Promotes Survival of Retinal Ganglion Cells after Damage In Vivo,” [cited by applicant]
Ying et al., “Metformin inhibits ALK1-mediated angiogenesis via activation of AMPK,” [cited by applicant]
Japanese Patent Office, International Search Report in International Patent Application No. PCT/JP2019/042107 (Nov. 26, 2019). [cited by applicant]